HomePTCT • NASDAQ
add
PTC Therapeutics, Inc.
Nakaraang pagsara
$75.76
Sakop ng araw
$74.83 - $79.03
Sakop ng taon
$35.95 - $87.50
Market cap
6.30B USD
Average na Volume
1.89M
P/E ratio
9.37
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 211.01M | 7.23% |
Gastos sa pagpapatakbo | 91.58M | 19.72% |
Net na kita | 15.90M | 114.90% |
Net profit margin | 7.53 | 113.89% |
Kita sa bawat share | 0.19 | 113.79% |
EBITDA | 14.60M | 132.10% |
Aktuwal na % ng binabayarang buwis | 168.89% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 1.71B | 66.83% |
Kabuuang asset | 2.64B | 43.50% |
Kabuuang sagutin | 2.80B | -3.35% |
Kabuuang equity | -155.76M | — |
Natitirang share | 80.29M | — |
Presyo para makapag-book | -38.85 | — |
Return on assets | 0.33% | — |
Return on capital | 0.38% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 15.90M | 114.90% |
Cash mula sa mga operasyon | -66.30M | 13.89% |
Cash mula sa pag-invest | -289.62M | -578.67% |
Cash mula sa financing | 15.22M | 186.34% |
Net change in cash | -346.77M | -169.33% |
Malayang cash flow | -326.80M | -599.26% |
Tungkol
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Itinatag
Ene 1, 1998
Headquarters
Website
Mga Empleyado
939
